Pharma RSS Digest - 2026-05-28

Overview

The 48-hour window closing May 28 was dominated by company-specific catalysts rather than broad market-moving events. The most clinically significant development was Antengene receiving Chinese regulatory endorsement to advance its Claudin 18.2 antibody-drug conjugate into a pivotal Phase III study for gastric cancer, marking a notable transition from early-stage to late-stage development in a competitive oncology target. On the manufacturing front, CordenPharma's agreement to acquire AmbioPharm reflects continued appetite for peptide contract manufacturing capacity, with the deal expanding CordenPharma's U.S.-based capabilities amid growing demand for domestic supply chains. A third strategic development involved Qualitas Dental Partners expanding its credit facilities with Live Oak Bank, signaling sustained interest in doctor-led consolidation models within dental care. The watchlist includes a Medline Class I recall affecting interventional devices, a large-scale Insulet insulin pod correction, and notable Phase III data publication for Jazz Pharmaceuticals' HER2-targeted therapy.

Key Developments

Antengene Initiates Phase III CLINCH-3 Study for ATG-022 in CLDN18.2+ Gastric Cancer

Antengene clinical trial update

Antengene announced that China's Center for Drug Evaluation (CDE) endorsed initiation of the pivotal Phase III CLINCH-3 study for ATG-022, the company's Claudin 18.2 (CLDN18.2) antibody-drug conjugate, in patients with CLDN18.2+ advanced gastric or gastroesophageal junction adenocarcinoma. The randomized, multicenter trial will evaluate ATG-022 versus investigator's choice, with progression-free survival and overall survival as primary endpoints. Prior Phase I/II data showed an objective response rate of 46.7% and disease control rate of 86.7% at the 1.8 mg/kg dose, with a median progression-free survival of 6.97 months. The company had previously received Breakthrough Therapy Designation, which facilitated regulatory discussions. Prof. Lin Shen from Peking University Cancer Hospital will serve as principal investigator.

CordenPharma Acquires AmbioPharm to partnership update

The initiation represents a meaningful advancement for Antengene as ATG-022 moves into late-stage development, potentially positioning the program for future marketing applications. The CLDN18.2-targeting ADC space is becoming increasingly crowded, making the multi-regional trial design notable as it suggests Antengene is building toward global regulatory submissions rather than limiting the asset to China. Success in this indication could address significant unmet need given limited third-line treatment options for gastric cancer patients. The upcoming data readout timeline and whether the Phase III results replicate the encouraging Phase I/II response rates will be critical to watch.

Qualitas Dental Partners partnership update

CordenPharma Acquires AmbioPharm to Expand Global Peptide API Manufacturing Footprint

CordenPharma entered into an agreement to acquire AmbioPharm, a U.S.-headquartered peptide contract development and manufacturing organization (CDMO), expanding its global peptide API capacity. AmbioPharm operates facilities in North Augusta, South Carolina and Shanghai, China, employing approximately 400 people across its two sites. The acquisition gives CordenPharma its second U.S.-based peptide facility and adds purification and lyophilization capabilities for U.S.-based commercial peptide API supply. The deal complements existing capabilities at CordenPharma Colorado, enabling fully U.S.-based peptide manufacturing options for large-scale commercial projects. Following closing, CordenPharma will operate peptide capabilities across three continents. The transaction remains subject to customary closing conditions with undisclosed financial terms, though AmbioPharm shareholders will reinvest into the combined business. BNP Paribas served as exclusive financial advisor to AmbioPharm.

The acquisition reinforces CordenPharma's position as a leading peptide CDMO amid growing demand for complex peptide active pharmaceutical ingredients. The addition of U.S.-based purification and lyophilization capacity is strategically relevant given increasing interest in domestic supply chains for pharmaceutical intermediates. The shareholder reinvestment signals confidence in the combined platform's growth potential. The transaction closing timeline and integration execution across the U.S. and China facilities represent near-term watchpoints, along with whether the expanded capacity attracts new customer commitments.

Qualitas Dental Partners Expands Credit Facilities to Support Regional Growth

Qualitas Dental Partners announced it has expanded its credit acquisition facilities with Live Oak Bank to support continued growth across Southern New England. The expanded facilities are designed to fund future practice partnerships in the region and complement recent investments to enlarge existing practices. The growth initiative is driven by strong interest from dental practices seeking to align with Qualitas' doctor-led partnership model, which emphasizes clinical autonomy and coordinated care as an alternative to traditional private equity consolidation. The company reports that more providers are seeking collaborative alternatives to traditional consolidation models.

The expansion signals a trend of dental practices favoring doctor-led ownership structures over private equity consolidation, potentially reshaping competitive dynamics in dental service organization markets. Live Oak Bank's deepened commitment validates the dental partnership model as a viable investment, while the expanded acquisition capacity could accelerate consolidation in Southern New England. Whether other dental support organizations need to adapt their value propositions to compete for practice partnerships will be worth monitoring, as this model gains traction.

Watchlist

• Medline Namic Manifold Class I Recall: FDA classified a recall of certain Namic Manifolds as the most serious type after particulate contamination was found in the fluid path, posing risk of emboli if introduced into blood during interventional procedures. Medland has advised immediate removal, quarantine, and destruction of affected devices. [link]
• Insulet Omnipod Pod Correction: Insulet initiated a voluntary correction for approximately 7 million Omnipod 5, DASH, and Eros pods due to a manufacturing defect causing cannula tears that can lead to insulin under-delivery. Globally, 24 serious adverse events including hospitalizations and diabetic ketoacidosis have been reported. The company is providing free replacements with no anticipated supply disruption. [link]
• Jazz Pharmaceuticals Zanidatamab Phase III Results Published in NEJM: HERIZON-GEA-01 trial demonstrated zanidatamab-containing combinations achieved median progression-free survival of 12.4 months versus 8.1 months for trastuzumab plus chemotherapy, and statistically significant overall survival benefit when combined with tislelizumab. The data has been submitted to NCCN for guideline inclusion. [link]
• Binaytara Cancer Hospital Environmental Approval: Nepal's government granted Environmental Impact Assessment approval for a $30 million, 200-bed comprehensive cancer hospital in Madhesh Province, the region's first such facility. Construction is expected to begin near the company's existing cancer center. [link]